Permeability of the blood-brain barrier in Alzheimer’s disease (PEBBAL) measured using dynamic contrast-enhanced MRI: a pilot study
Theme Group:
Clinical Trials and Therapeutics
About the project:
Inflammation is the body’s normal response to injury and infection. It can be healthy or harmful depending on the situation. We know that when people with dementia get infections their memory symptoms can get worse. Blood vessels normally block the entry of bacteria and chemicals into the brain, which if allowed to enter would cause damage to nerve cells. This defence is called the blood-brain barrier (BBB). Research studies have measured how much of a chemical contrast moves from the blood into the brain using a brain scan and suggested that the BBB may become leakier in dementia. We have developed a more accurate method to measure BBB leakiness, using these brain scans.
We are interested in how the BBB, inflammation and dementia are linked. We believe that with our improved method of measuring BBB leakiness, this study could lead to new information about the cause of dementia and help us to predict those people with Alzheimer’s disease who may get worse more quickly. This pilot project will be an observational clinical study with cross-sectional and longitudinal components, exploring BBB permeability and systemic inflammation in AD participants and controls.
Key iDeAC expertise:

Dr Jessica Teeling
Neuroinflammation and infection

Dr Jay Amin
Clinical Trials

Dr Ian Galea
Translational diagnostics

Dr Angela Darekar
Imaging (human)
Related projects:
Use of antisense oligonucleotide in Progressive supranuclear palsy
Treating impulsivity in people with progressive supranuclear palsy
Using electronic patient records to examine patient outcomes in Dementia with Lewy bodies
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Phase 1 trial of bepranemab in progressive supranuclear palsy
Permeability of the blood-brain barrier in Alzheimer’s disease (PEBBAL) measured using dynamic contrast-enhanced MRI: a pilot study
Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease (BIO-AGE)
